[go: up one dir, main page]

WO2008099913A1 - ヒトhmgb-1に特異的に結合する抗体を有効成分として含有する治療剤 - Google Patents

ヒトhmgb-1に特異的に結合する抗体を有効成分として含有する治療剤 Download PDF

Info

Publication number
WO2008099913A1
WO2008099913A1 PCT/JP2008/052500 JP2008052500W WO2008099913A1 WO 2008099913 A1 WO2008099913 A1 WO 2008099913A1 JP 2008052500 W JP2008052500 W JP 2008052500W WO 2008099913 A1 WO2008099913 A1 WO 2008099913A1
Authority
WO
WIPO (PCT)
Prior art keywords
hmgb
antibody
active ingredient
therapeutic agent
antibody capable
Prior art date
Application number
PCT/JP2008/052500
Other languages
English (en)
French (fr)
Inventor
Yukio Ando
Ikuro Maruyama
Shingo Yamada
Original Assignee
Kumamoto University
Kagoshima University
Shino-Test Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kumamoto University, Kagoshima University, Shino-Test Corporation filed Critical Kumamoto University
Priority to JP2008558144A priority Critical patent/JP5225109B2/ja
Priority to EP08711330A priority patent/EP2123297A4/en
Priority to US12/449,543 priority patent/US8470325B2/en
Publication of WO2008099913A1 publication Critical patent/WO2008099913A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

　従来、HMGB-2に結合することなくHMGB-1に特異的に結合し、かつ親和性の高い抗体を得ることは容易ではなかった。このような中、本発明者らは、特定のペプチドを抗原として用いることによって、HMGB-2よりもHMGB-1に強く反応する抗体を取得することに成功した。また本発明者らは、上記抗体がHMGB-1に対して中和活性を有することを見出した。本発明者らは、上記抗体をアミロイドシスの疾患モデル動物に投与した結果、顕著な治療効果が得られることを実証することに成功した。
PCT/JP2008/052500 2007-02-15 2008-02-15 ヒトhmgb-1に特異的に結合する抗体を有効成分として含有する治療剤 WO2008099913A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2008558144A JP5225109B2 (ja) 2007-02-15 2008-02-15 ヒトｈｍｇｂ−１に特異的に結合する抗体を有効成分として含有する治療剤
EP08711330A EP2123297A4 (en) 2007-02-15 2008-02-15 THERAPEUTIC AGENT WITH AN ANTIBODY FOR SPECIFIC BINDING TO HUMAN HMGB-1 AS AN ACTIVE SUBSTANCE
US12/449,543 US8470325B2 (en) 2007-02-15 2008-02-15 Method of treating amykloidosis comprising administering an anti-HMGB-1 antibody

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007034325 2007-02-15
JP2007-034325 2007-02-15

Publications (1)

Publication Number Publication Date
WO2008099913A1 true WO2008099913A1 (ja) 2008-08-21

Family

ID=39690138

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/052500 WO2008099913A1 (ja) 2007-02-15 2008-02-15 ヒトhmgb-1に特異的に結合する抗体を有効成分として含有する治療剤

Country Status (5)

Country Link
US (1) US8470325B2 (ja)
EP (1) EP2123297A4 (ja)
JP (1) JP5225109B2 (ja)
TW (1) TW200902063A (ja)
WO (1) WO2008099913A1 (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020059847A1 (ja) 2018-09-21 2020-03-26 国立大学法人 東京医科歯科大学 ヒトｈｍｇｂ１に特異的に結合するヒトモノクローナル抗体、及びそれを含有するアルツハイマー病を治療又は予防するための医薬組成物
US10730937B2 (en) 2016-08-09 2020-08-04 National University Corporation Tokyo Medical And Dental University Antibodies against HMB1, and composition comprising same for treating or preventing alzheimer's disease

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200900077A (en) * 2007-02-15 2009-01-01 Univ Kyushu Nat Univ Corp Therapeutic agent for interstitial pulmonary disease comprising anti-HMGB-1 antibody
JP5285437B2 (ja) * 2007-02-15 2013-09-11 学校法人福岡大学 抗ｈｍｇｂ−１抗体を含む臓器移植拒絶抑制剤
FI20105715A0 (fi) 2010-06-18 2010-06-18 Helsingin Yliopisto Asetyloituun HMGB1:een sitoutuva polyklonaalinen vasta-aine
WO2014110225A1 (en) * 2013-01-09 2014-07-17 The Feinstein Institute For Medical Research Hmgb1-binding beads and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003534351A (ja) * 2000-05-22 2003-11-18 ニュー・ヨーク・ユニヴァーシティー アミロイドβ及びアミロイド沈着物に対する免疫応答誘導のための、アミロイドβと相同的な、合成の、免疫原性だが非アミロイド原性ペプチド
JP2004107260A (ja) * 2002-09-18 2004-04-08 Takeda Chem Ind Ltd 脳アミロイドーシス予防・治療薬のスクリーニング方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62166897A (ja) 1986-01-20 1987-07-23 Toyo Soda Mfg Co Ltd 核内非ヒストン蛋白質に対するモノクロ−ナル抗体
EP0727487A1 (en) 1995-02-17 1996-08-21 K.U. Leuven Research & Development Multiple-tumor aberrant growth genes
WO1998002744A1 (fr) 1996-07-17 1998-01-22 Kaneka Corporation Medicaments pour le diagnostic de maladies auto-immunes
JP3267893B2 (ja) 1997-05-15 2002-03-25 鐘淵化学工業株式会社 自己免疫疾患の診断薬
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US6794132B2 (en) 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies
US7754217B2 (en) 2001-03-16 2010-07-13 Bio3 Research Srl HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases
CN100447154C (zh) 2001-05-15 2008-12-31 费因斯坦医学研究学院 利用hmg片段作为抗炎症试剂
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
US7220723B2 (en) 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
JP4823465B2 (ja) 2001-07-13 2011-11-24 株式会社シノテスト ヒトｈｍｇ−１に特異的に結合する抗体並びにこの抗体を用いるヒトｈｍｇ−１の免疫学的測定方法及び免疫学的測定試薬
ITMI20011986A1 (it) 2001-09-25 2003-03-25 San Raffaele Centro Fond Metodo e composizione per l'attivazione di cellule presentanti l'antigene
CA2470640A1 (en) 2001-12-19 2003-06-26 Alcedo Biotech Gmbh Use of hmgb proteins and nucleic acids that code therefor
CA2491321A1 (en) 2002-07-03 2004-01-15 Fondazione Centro San Raffaele Del Monte Tabor Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair
GB0226251D0 (en) 2002-11-11 2002-12-18 San Raffaele Centro Fond Acetylated protein
JP2006510619A (ja) 2002-11-20 2006-03-30 クリティカル セラピューティクス，インコーポレイテッド 抗炎症剤としてのｈｍｇｂ断片の使用
EP1567544A4 (en) 2002-11-20 2009-07-22 Long Island Jewish Res Inst USE OF HMGB POLYPEPTIDES TO INCREASE IMMUNE RESPONSES
US20040141948A1 (en) 2002-11-20 2004-07-22 Critical Therapeutics, Inc. Use of HMGB fragments as anti-inflammatory agents
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
CA2882022A1 (en) * 2003-09-11 2005-03-24 Walter Newman Monoclonal antibodies against hmgb1
ITRM20040058A1 (it) 2004-02-03 2004-05-03 Marco E Bianchi Inibitori ed antagonisti di hmgb1 in grado di regolare la proliferazione delle cellule muscolari lisce ed endoteliali.
CA2585043A1 (en) 2004-10-22 2007-01-04 Medimmune, Inc. High affinity antibodies against hmgb1 and methods of use thereof
EP1907003A2 (en) 2005-05-13 2008-04-09 The Feinstein Institute for Medical Research Combination therapy with inhibitors of hmgb and caspase for the treatment of inflammatory diseases
EP2364998A1 (en) 2005-06-16 2011-09-14 The Feinstein Institute for Medical Research Antibodies against HMGB1 and fragments thereof
AU2007248784B2 (en) 2006-05-05 2013-11-21 Vtv Therapeutics Llc RAGE fusion proteins, formulations, and methods of use thereof
JP5285437B2 (ja) 2007-02-15 2013-09-11 学校法人福岡大学 抗ｈｍｇｂ−１抗体を含む臓器移植拒絶抑制剤
TW200900077A (en) 2007-02-15 2009-01-01 Univ Kyushu Nat Univ Corp Therapeutic agent for interstitial pulmonary disease comprising anti-HMGB-1 antibody

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003534351A (ja) * 2000-05-22 2003-11-18 ニュー・ヨーク・ユニヴァーシティー アミロイドβ及びアミロイド沈着物に対する免疫応答誘導のための、アミロイドβと相同的な、合成の、免疫原性だが非アミロイド原性ペプチド
JP2004107260A (ja) * 2002-09-18 2004-04-08 Takeda Chem Ind Ltd 脳アミロイドーシス予防・治療薬のスクリーニング方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2123297A4 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10730937B2 (en) 2016-08-09 2020-08-04 National University Corporation Tokyo Medical And Dental University Antibodies against HMB1, and composition comprising same for treating or preventing alzheimer's disease
WO2020059847A1 (ja) 2018-09-21 2020-03-26 国立大学法人 東京医科歯科大学 ヒトｈｍｇｂ１に特異的に結合するヒトモノクローナル抗体、及びそれを含有するアルツハイマー病を治療又は予防するための医薬組成物

Also Published As

Publication number Publication date
US8470325B2 (en) 2013-06-25
US20110229487A1 (en) 2011-09-22
EP2123297A4 (en) 2011-10-12
TW200902063A (en) 2009-01-16
EP2123297A1 (en) 2009-11-25
JP5225109B2 (ja) 2013-07-03
JPWO2008099913A1 (ja) 2010-05-27

Similar Documents

Publication Publication Date Title
NZ598524A (en) Therapeutic dll4 binding proteins
WO2004016750A3 (en) FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
WO2007115049A3 (en) Humanized monoclonal antibodies to hepatocyte growth factor
WO2008099913A1 (ja) ヒトhmgb-1に特異的に結合する抗体を有効成分として含有する治療剤
WO2007143098A8 (en) Hepatocyte growth factor (hgf) binding proteins
WO2008036341A3 (en) Compositions and methods relating to glucagon receptor antibodies
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
WO2009133137A3 (en) Pegylated recombinant human growth hormone compounds
EP4279512A3 (en) Cytotoxicity-inducing therapeutic agent
JOP20210044A1 (ar) الأجسام المضادة لـ cd38
WO2006033700A3 (en) Her2 antibody composition
UA94734C2 (ru) ТЕРАПЕВТИЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С b-АМИЛОИДНЫМ ПЕПТИДОМ
WO2008085562A3 (en) Combinatorieal therapy of cancer and infectious diseases with anti-b7-h1 antibodies
WO2008136869A3 (en) Methods and compositions related to targeting wounds, regenerating tissue, and tumors
EP2628749A3 (en) Antimicrobial kinocidin compostions and methods of use
EA200801427A1 (ru) Молекулы антитела со специфической активностью в отношении интерлейкина-6 (ил-6) человека
WO2009051220A1 (ja) Aβオリゴマーに特異的に結合する抗体およびその利用
WO2009072598A1 (ja) 掻痒症治療剤
WO2006108670A3 (en) Use of cd25 antibodies in immunotherapy
WO2009054471A1 (ja) 免疫誘導剤
WO2013061083A3 (en) Therapeutic agents and uses thereof
WO2008049990A3 (fr) Utilisation d'un anticorps anti-cd151 pour le traitement du cancer
WO2009099642A3 (en) Proteomic analysis of active multiple sclerosis lesions
WO2007056301A3 (en) Antibody therapy for treatment of diseases associated with gluten intolerance
WO2007124446A3 (en) Device for delivery of agents to and through the human scalp

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08711330

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2008558144

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008711330

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12449543

Country of ref document: US